Does Medicaid Cover Farxiga?

Farxiga's coverage story changed in a real way this year. For most of its time on the market, "does Medicaid cover Farxiga" had roughly the same answer as its rival Jardiance — probably, with paperwork. Then, in April 2026, the FDA approved the first generic dapagliflozin, and that shifted how state Medicaid programs treat the brand. This guide walks through what's covered, what changed, what you'll pay, and what to do if your specific state or plan says no.

1. How Medicaid Coverage for Farxiga Works

Every state Medicaid program runs a Preferred Drug List (PDL) that sorts medications into preferred and non-preferred tiers within each drug class. Preferred drugs are usually dispensed without extra steps; non-preferred drugs require a prior authorization request from your prescriber before the pharmacy can bill Medicaid.

Brand-name Farxiga has historically sat in the non-preferred tier in most states because of its cost. That's still true today, but with an added wrinkle: many states now use the new generic dapagliflozin as their preferred SGLT2 inhibitor for diabetes and heart failure, which means brand Farxiga requires justification for why the generic won't work for you.

2. Why Coverage Varies by State

Medicaid is jointly funded by the federal government and each state, and states retain broad control over their own formularies and prior authorization rules. In states that use managed care, multiple private insurers — such as Buckeye Health Plan, CareSource, Molina, and UnitedHealthcare Community Plan — may each administer the pharmacy benefit with their own criteria, layered on top of the state's baseline rules.

• Fee-for-service states run one statewide Medicaid pharmacy formulary directly.
• Unified PDL states, like Ohio, apply the same preferred drug list across every managed care plan in the state, which makes prior authorization criteria more predictable.
• Non-unified managed care states allow each plan more latitude, so the exact same prescription can be approved instantly under one plan and require a multi-step appeal under another.

3. The Generic Dapagliflozin Factor

This is the single biggest change affecting Farxiga coverage in 2026, and it's worth understanding on its own.

• What happened: On April 6–7, 2026, the FDA approved the first true generic versions of dapagliflozin tablets from multiple manufacturers.
• What it covers: The generic's labeling matches brand Farxiga for type 2 diabetes (improving glycemic control) and for reducing the risk of heart failure hospitalization in adults with type 2 diabetes and cardiovascular risk.
• What it doesn't cover yet: The generic's FDA labeling currently excludes the chronic kidney disease indication — reducing the risk of kidney disease progression, kidney failure, and cardiovascular death in CKD. That use still requires brand-name Farxiga or AstraZeneca's authorized generic.
• What it means for Medicaid: If you're prescribed Farxiga for diabetes or heart failure, expect your state Medicaid plan to ask you to try or switch to generic dapagliflozin first. If you're prescribed it specifically for CKD, that step-therapy requirement usually doesn't apply, since the generic isn't approved for that use.

4. State-by-State Coverage Examples

These examples show the range of approaches — always confirm your own state and specific plan.

5. Prior Authorization: What's Required

Exact forms differ by state, but most Medicaid prior authorization requests for Farxiga ask your prescriber to document one or more of the following:

• A qualifying diagnosis — type 2 diabetes, heart failure (reduced or preserved ejection fraction), or chronic kidney disease at risk of progression.
• Step therapy with generic dapagliflozin — for diabetes and heart failure prescriptions, proof that the generic wasn't appropriate or didn't work, before brand Farxiga is approved.
• Step therapy with metformin — many states still require first-line metformin to have been tried for the type 2 diabetes indication specifically.
• Relevant lab values — HbA1c, kidney function (eGFR), or ejection fraction, depending on the indication.

6. New 2026 Prior Authorization Timeline Rules

A federal rule that took effect in January 2026 — CMS-0057-F — changed how fast Medicaid managed care plans, Medicare Advantage plans, and ACA marketplace plans have to respond to prior authorization requests.

• Standard requests: A decision within 7 calendar days.
• Urgent requests: A decision within 72 hours.
• Specific denial reasons required: Plans must now provide a specific, documented reason for every prior authorization denial, rather than a generic rejection.

This is a meaningful improvement over prior years, when PA turnaround times could stretch far longer with little accountability. If your request has been pending well beyond these windows, that's grounds to follow up directly with your plan.

7. What You'll Pay: The Medicaid Copay

Federal rules cap how much Medicaid programs can charge for prescription copays, which is why even a several-hundred-dollar brand-name drug rarely costs more than a handful of dollars once approved.

8. If Medicaid Doesn't Cover Farxiga for You

• Ask about generic dapagliflozin first. If your prescription is for diabetes or heart failure, the generic is very likely to be approved faster and cheaper than an appeal for the brand.
• File an appeal for the brand if clinically necessary. If you've had an adverse reaction to the generic, or your prescription is specifically for chronic kidney disease, document that clearly — this is exactly the scenario brand-name approval exists for.
• Ask about a preferred alternative. Jardiance (empagliflozin) is another SGLT2 inhibitor with overlapping approved uses and may sit differently on your state's formulary.
• Request an expedited review if a delay could seriously affect your health — most states must respond within 72 hours for urgent cases under the new CMS rule.

9. Medicaid Eligibility Basics

Before Farxiga coverage is relevant, you need to qualify for Medicaid itself, which depends on your state, household size, income, and eligibility category.

• Expansion-state adults: In the 41 states plus D.C. that expanded Medicaid under the ACA, most adults under 65 qualify with household income up to 138% of the federal poverty level.
• Non-expansion states: Ten states have not expanded Medicaid; in these states, non-disabled adults without dependent children generally cannot qualify based on income alone.
• Children: Every state covers children at significantly higher income limits, often 200%–300%+ FPL through Medicaid and CHIP combined.
• Pregnant individuals: All states cover pregnant enrollees at or above 138% FPL, with many extending eligibility well beyond that.
• Seniors and people with disabilities: Eligibility runs through disability-linked pathways with different income and asset tests than standard MAGI Medicaid.

10. Income Limit Comparison

These figures apply in the 41 expansion states plus D.C. using 2026 federal poverty guidelines. Non-expansion states set their own, generally lower, limits and often exclude childless adults from income-based eligibility entirely. Figures update annually — confirm your state's current numbers before assuming eligibility.

11. Covered Medications Comparison

Understanding where Farxiga and its generic sit relative to other diabetes, heart failure, and kidney-protection medications helps explain the prior authorization logic.

Manufacturers behind these alternative classes run their own assistance programs — see NovoCare for Novo Nordisk's GLP-1 medications, or Lilly Cares if your prescriber discusses switching to Jardiance instead.

12. Cash Price Without Any Coverage

If you're between coverage, waiting on a Medicaid application, or your prior authorization is pending, here's the baseline to plan around.

The generic's price is still settling as more manufacturers enter the market, so it's worth comparing a few pharmacies with a drug price checker before you fill, especially while Medicaid paperwork is pending.

13. Farxiga Savings Card and Patient Assistance

These AstraZeneca programs matter most for people who aren't covered by Medicaid — and one of them changed significantly in 2026 because of the new generic.

• Farxiga Savings Card: For commercially insured patients, reduces your copay to as low as $0 per 30-day supply, with savings capped around $175 per fill. A separate cash-pay instant-savings option can take up to $150 off each fill for patients paying without insurance. By its own terms, the card explicitly excludes anyone whose prescription is reimbursed in whole or in part by Medicaid, Medicare, or another government program.
• AZ&Me Patient Assistance Program: Historically provided free Farxiga to uninsured patients with income at or below 300% of the federal poverty level. As of May 1, 2026, AZ&Me stopped accepting new applicants for Farxiga and Xigduo XR, specifically because the new generic makes low-cost access available another way. Patients already enrolled before that date continue receiving support through December 31, 2026.

14. Medicaid vs. Medicare vs. Commercial Insurance

For more on how the 2026 Medicare negotiated price and the $2,100 out-of-pocket cap work together, see our Medicare Part D 2026 changes guide. Extra Help recipients pay between roughly $4.50 and $11.20 per fill — see our Extra Help eligibility guide to check if you qualify.

15. Step-by-Step: Getting Farxiga Approved

16. Applying for Medicaid Itself

• Where to apply: Through your state's Medicaid agency or the federal Health Insurance Marketplace at healthcare.gov, which routes eligible applicants to Medicaid automatically.
• What you'll need: Proof of income, household size, state residency, and citizenship or immigration status.
• No enrollment period required: Unlike ACA marketplace plans, Medicaid accepts applications year-round.
• Retroactive coverage: Many states can cover medical bills from up to three months before your application date if you were eligible during that period.

17. Approval Timelines

18. Renewal: Medicaid and Prior Authorization

• Medicaid eligibility redetermination generally happens annually — states will contact you to confirm your income and household information still qualify.
• Prior authorization for Farxiga often needs periodic renewal, commonly annually, even if your diagnosis hasn't changed.
• Respond promptly to renewal notices. Missing a redetermination deadline is one of the most common reasons people lose Medicaid coverage unnecessarily.
• Report income or household changes during the year — they can affect both your Medicaid eligibility and which programs you might newly qualify for.

19. Common Mistakes to Avoid

20. Pros and Cons of Medicaid Coverage

21. Decision Tree: What's Your Next Step?

22. Real Patient Scenarios